<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609869</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14978</org_study_id>
    <secondary_id>RV-CLL-PI-067</secondary_id>
    <nct_id>NCT00609869</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab</brief_title>
  <official_title>A Phase II Study of Lenalidomide (REVLIMID®) in Combination With Rituximab for Patients With CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the use of Rituximab in combination with Revlimid
      in the treatment of refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia
      (CLL). Revlimid® is a drug that changes the immune system and it may also get in the way with
      the growth of tiny blood vessels that help support tumor growth. Therefore, in theory, it may
      reduce or prevent the growth of cancer cells. Revlimid® is approved by the Food and Drug
      Administration (FDA) for the treatment of specific types of Myelodysplasia syndrome (MDS) and
      Multiple Myeloma, two different types of blood cancer. It is currently being tested in a
      variety of cancer conditions. In this case it is considered experimental.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II trial will use a Simon's two stage design enrolling a total of 28 subjects. Ten
      will be accrued during stage 1 and 18 during stage 2. If 3 or fewer responses (CR+PR) are
      observed during the first stage then the trial is stopped early. Given that the 'true'
      response probability is 30%, there is a 64.96% probability of ending the trial during stage
      1. However, if the 'true' response probability is 60% then there is a 5.48% probability that
      the trial will be stopped in stage 1. If more than 3 responses are observed in stage 1,
      another 18 patients will be accrued in stage 2. If 12 or fewer responses are observed by the
      end of the trial, then no further investigation of the drug is warranted. Otherwise, conclude
      that the drug is worthy of further investigation. The alpha level of the design is 0.04 and
      the power is 0.91.

      Patients with confirmed CD5+/CD20+ MCL or CLL who have relapsed or progressed after Rituximab
      therapy following a minimum of 6 months duration of response (SD, PR, or CR as defined by
      Appendix D) will be eligible for this study. Baseline evaluation of patients prior to
      enrollment in this study will include complete blood counts (CBCs), serum chemistries, liver
      function tests, kidney function tests, lactate dehydrogenase (LDH); and CT scans of the
      chest, abdomen and pelvis; and bone marrow biopsy. The exact values for the status of organ
      function allowable on this protocol are included in the body of this document. Bone marrow
      aspirates, biopsies and standard FISH evaluation for specific cytogenetic abnormalities will
      be obtained by the clinical site. An adequate bone marrow aspirate sample is required for a
      subject to be eligible to participate in this study. All assessments will be completed
      according to Schedule of Study Assessments.

      Patients who meet eligibility criteria and have signed the informed consents will have
      further laboratory evaluation which will involve flow cytometry of the peripheral blood to
      evaluate: 1) CD20 density on the leukemic cells (CLL patients only), 2) the percentage of
      CD56+ cells to evaluate the baseline level of natural killer (NK) cell, 3) the density of
      activation antigens (CD2, CD11a, CD31, CD38, and CD69) on CD56+ cells, and 4) CD38 (ZAP-70)
      expression. Pretreatment serum baseline values for Interferon-alpha (IFN-alpha), Tumor
      necrosis factor-alpha (TNF-A), granulocyte-macrophage colony-stimulating factor (GM-CSF),
      IL-6, and soluble IL-2 receptor will be obtained. A baseline CBC, flow cytometry and cytokine
      studies will be obtained on Day 1 prior to start of Lenalidomide.

      All patients will have a full immunological evaluation on Day 15 of Lenalidomide therapy
      prior to Rituximab administration. A bone marrow biopsy will be performed on all patients
      (CLL and MCL) with prior documented bone marrow involvement once between Days 13- 15 to
      assess the impact of the lenalidomide on the malignant cells and the surface density of CD20
      for patients with CLL before the administration of Rituximab. Flow cytometry on the aspirate
      specimen will be performed at Moffitt Cancer Center. The cytokine studies will be drawn on
      Day 15, prior to the administration of Rituximab. Starting on Day 15 after collection of
      specimens, the patients will receive four weekly doses of Rituximab (375 mg/m^2) concurrent
      with lenalidomide as per the cycle schedule. Lenalidomide therapy will be continued until
      progression of disease, unacceptable toxicity or patient withdrawal.

      Patient assessment during the clinical trial will be performed by a physician and will occur
      prior to the administration of each dose of Rituximab. The evaluation will include CBC,
      routine chemistries, kidney function, liver function, and LDH. The impact of the treatment on
      any lymphadenopathy or splenomegaly will be documented. Any toxicities noted during these
      evaluations will be noted. After the four weekly doses of Rituximab, if the pretreatment bone
      marrow biopsy was positive, the patient will have a repeat bone marrow biopsy to assess
      response. If the patient had splenomegaly or lymphadenopathy prior to entry into the trial,
      the patient will need repeat CT scans to assess response. The scans and bone marrow biopsies
      should be performed two weeks after the patient's last dose of Rituximab.

      Follow-up of patients after completing the Rituximab treatment for patients who have not
      progressed while on therapy will involve a CBC, routine chemistries, liver function tests,
      and LDH drawn according to the Schedule of Assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The sum of Complete Remission (CR) plus Partial Remission (PR) rates. Duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, and must be confirmed greater than 8 weeks after first meeting CR or PR criteria. Response and progression for Chronic Lymphocytic Leukemia (CLL) were evaluated using 2008 updated National Cancer Institute-Sponsored Working Group Guidelines (NCI-WG) for Chronic Lymphocytic Leukemia. CR: all of the criteria must be met, and patients have the lack disease-related constitutional symptoms: PR: at least two of the criteria of Group A plus one of the criteria of group B have to be met. Group A Parameters: Lymphadenopathy; Hepatomegaly; Splenomegaly; Blood; Lymphocytes; Marrow. Group B Parameters: Platelet count; Hemoglobin; Neutrophils.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The ORR rate plus Stable Disease (SD). NCI-WG: SD is the absence of progressive disease (PD) and failure to achieve at least a PR; PD: at least one of the criteria of Group A or Group B has to be met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Treatment Failure (TTF)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The time from start of therapy to death, Progressive Disease (PD) or initiation of next therapy. PD: at least one of the NCI-WG criteria of Group A or Group B has to be met.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Lymphocytic Leukemia</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide and Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.
Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.
Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.</description>
    <arm_group_label>Lenalidomide and Rituximab</arm_group_label>
    <other_name>REVLIMID®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab was administered at 375 mg/m^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.</description>
    <arm_group_label>Lenalidomide and Rituximab</arm_group_label>
    <other_name>RITUXAN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically or cytologically confirmed CD5+/CD20+ B-Cell Chronic Lymphocytic
             Leukemia or Mantle Cell Lymphoma

          -  Meet the following CLL criteria to participate in this study:

               -  Absolute lymphocyte count &gt; 5000/μL

               -  CD20+ and CD5+

               -  Atypical cells representing &lt; 55% on the peripheral smear

               -  Bone marrow lymphocytes ≥ 30%

               -  Or previous confirmed diagnosis of CLL/small lymphocytic lymphoma (SLL) with less
                  than 5000/μl or less than 30% lymphocytes in BM

          -  CLL Patients are eligible if they have stage III or IV disease. Patients with stage 0,
             I or II disease will be eligible if they have evidence of active disease defined as
             one or more of the following signs/symptoms:

               -  Documented weight loss of ≥ 10% over a six month period

               -  Febrile episodes of 38 degrees Celsius (100.5 degrees F) or greater for greater
                  than 2 weeks without evidence of infection

               -  Massive or progressive splenomegaly defined as &gt; 6 cm below the left costal
                  margin

               -  Massive (&gt; 10 cm in longest diameter) or progressive lymphadenopathy

          -  Patients with progressive lymphadenopathy will need a biopsy of the lymphadenopathy
             within the previous six months to ensure that the disease entity remains chronic
             lymphocytic leukemia. Lymph node biopsy can be deferred if the patient does not have
             superficial lymphadenopathy that is easily accessible by surgery or by CT guided
             biopsy.

          -  The diagnosis of MCL is based upon the National Comprehensive Cancer Network (NCCN)
             guidelines. The patient's will have biopsy proven CD5+/CD20+/CD23- mantle cell
             lymphoma with the characteristic cytogenetic abnormality t(11;14) or a cyclin D1
             positive immunophenotype. If malignancy is CD23+ but FISH positive for t(11;14),
             diagnosis of mantle cell lymphoma can be made. Patients with mantle cell lymphoma
             require appropriate staging which would include upper and lower endoscopy within 2
             months of enrollment per NCCN guidelines without additional treatment since the
             endoscopies.

          -  Patients with MCL and CLL will be eligible if they have relapsed or progressive
             disease after Rituximab therapy or a combination therapy including Rituximab. Any
             other number of previous treatments is allowed including autologous or allogeneic bone
             marrow transplantation. Patients who are younger than age 65 who have not had a bone
             marrow transplant must be ineligible or have declined a bone marrow (BM) transplant to
             participate in this study. Although a transplant is not the standard of care for this
             patient population, it does provide the best opportunity for a cure.

          -  Anticipated life expectancy of &gt; 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Baseline organ and marrow function as follows:

               -  Absolute neutrophil count ≥1,500/µL

               -  Platelets ≥50,000/µL

               -  Total bilirubin ≤2.0 mg/dL (34 µmol/L)

               -  aspartic transaminase (AST)/alanine transaminase (ALT) ≤2.5 X institutional upper
                  limit of normal(ULN)

               -  Creatinine &lt; institutional ULN OR

               -  Creatinine clearance ≥60 mL/min/m² for patients with creatinine levels above
                  institutional ULN

          -  All study participants must be registered into the mandatory RevAssist® program, and
             be willing and able to comply with the requirements of RevAssist®. Women of
             childbearing potential, and men with a partner of childbearing potential must follow
             pregnancy test and birth control guidelines outlined for this study.

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Patients with uric acid levels &gt; ULN at baseline must be corrected to ≤ULN prior to
             the initiation of study therapy.

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering study or those who have not recovered
             from adverse events due to agents administered more than 4 weeks earlier.

          -  May not be receiving any other investigational agents

          -  Known brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to lenalidomide and/or thalidomide

          -  Prior desquamating (blistering) rash with thalidomide

          -  Neuropathy ≥ grade 2

          -  Uncontrolled intercurrent illness including (not limited to) ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Women currently pregnant or breastfeeding

          -  Known seropositive for or active viral infection with human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are
             seropositive because of hepatitis B virus vaccine are eligible.

          -  History of another malignancy besides CLL or MCL who have been disease-free ≤ 3 years
             with exception of basal cell or squamous cell carcinoma of skin or carcinoma in situ
             of cervix or breast

          -  Any serious medical condition or psychiatric illness that will prevent patient from
             signing the informed consent form or will place the patient at unacceptable risk if
             he/she participates in the study

          -  Prior use of lenalidomide

          -  Prior severe hypersensitivity to Rituximab or other murine products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Pinilla, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Cancer Care &amp; Research/Watson</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>August 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2014</results_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at Moffitt Cancer Center from October 31, 2007 to March, 22, 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Lenalidomide and Rituximab</title>
          <description>28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.
Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.
Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawn, ischemic stroke</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe hematologic toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Seizures</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe tumor flare reaction</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hepatitis B infection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Rituximab reaction prior to lenalidomide</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mantle cell: not evaluable</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Lenalidomide and Rituximab</title>
          <description>28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.
Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.
Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="41" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>The sum of Complete Remission (CR) plus Partial Remission (PR) rates. Duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, and must be confirmed greater than 8 weeks after first meeting CR or PR criteria. Response and progression for Chronic Lymphocytic Leukemia (CLL) were evaluated using 2008 updated National Cancer Institute-Sponsored Working Group Guidelines (NCI-WG) for Chronic Lymphocytic Leukemia. CR: all of the criteria must be met, and patients have the lack disease-related constitutional symptoms: PR: at least two of the criteria of Group A plus one of the criteria of group B have to be met. Group A Parameters: Lymphadenopathy; Hepatomegaly; Splenomegaly; Blood; Lymphocytes; Marrow. Group B Parameters: Platelet count; Hemoglobin; Neutrophils.</description>
        <time_frame>Up to 6 years</time_frame>
        <population>All evaluable chronic lymphocytic leukemia participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Lenalidomide and Rituximab</title>
            <description>28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.
Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.
Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>The sum of Complete Remission (CR) plus Partial Remission (PR) rates. Duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, and must be confirmed greater than 8 weeks after first meeting CR or PR criteria. Response and progression for Chronic Lymphocytic Leukemia (CLL) were evaluated using 2008 updated National Cancer Institute-Sponsored Working Group Guidelines (NCI-WG) for Chronic Lymphocytic Leukemia. CR: all of the criteria must be met, and patients have the lack disease-related constitutional symptoms: PR: at least two of the criteria of Group A plus one of the criteria of group B have to be met. Group A Parameters: Lymphadenopathy; Hepatomegaly; Splenomegaly; Blood; Lymphocytes; Marrow. Group B Parameters: Platelet count; Hemoglobin; Neutrophils.</description>
          <population>All evaluable chronic lymphocytic leukemia participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate</title>
        <description>The ORR rate plus Stable Disease (SD). NCI-WG: SD is the absence of progressive disease (PD) and failure to achieve at least a PR; PD: at least one of the criteria of Group A or Group B has to be met.</description>
        <time_frame>Up to 6 years</time_frame>
        <population>All evaluable chronic lymphocytic leukemia participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Lenalidomide and Rituximab</title>
            <description>28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.
Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.
Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate</title>
          <description>The ORR rate plus Stable Disease (SD). NCI-WG: SD is the absence of progressive disease (PD) and failure to achieve at least a PR; PD: at least one of the criteria of Group A or Group B has to be met.</description>
          <population>All evaluable chronic lymphocytic leukemia participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Treatment Failure (TTF)</title>
        <description>The time from start of therapy to death, Progressive Disease (PD) or initiation of next therapy. PD: at least one of the NCI-WG criteria of Group A or Group B has to be met.</description>
        <time_frame>Up to 6 years</time_frame>
        <population>All evaluable chronic lymphocytic leukemia participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Lenalidomide and Rituximab</title>
            <description>28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.
Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.
Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Treatment Failure (TTF)</title>
          <description>The time from start of therapy to death, Progressive Disease (PD) or initiation of next therapy. PD: at least one of the NCI-WG criteria of Group A or Group B has to be met.</description>
          <population>All evaluable chronic lymphocytic leukemia participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="5.6" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years, 3 months</time_frame>
      <desc>All participants</desc>
      <group_list>
        <group group_id="E1">
          <title>Experimental: Lenalidomide and Rituximab</title>
          <description>28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.
Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.
Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin - low</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC) - low</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Platelets - low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia - Other, AFib</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other, AFib/AFlu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other, cholilethiasis, gallbladder surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Disease progression NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Pain NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain NOS - Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Syndromes - Other, tumor fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tumor flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils – Bladder (urinary)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils – Blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils – Brain + Spinal cord (encephalomyelitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils – Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils – Upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection - Other, Port A Cath</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection - Other, unketiology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Blood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 ANC or Grade 1 or 2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other, chronic renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other, dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vascular - Other, CVA/CNS ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC) - low</sub_title>
                <counts group_id="E1" events="52" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemoglobin low</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Platelets - low</sub_title>
                <counts group_id="E1" events="23" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms -</sub_title>
                <counts group_id="E1" events="36" subjects_affected="18" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic) - Oral cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="70" subjects_affected="23" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="43" subjects_affected="14" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="21" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Lymph node</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Lymph node</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Oral cavity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Pain NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - Stomach</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tumor flare</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Bronchus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Sinus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy - possibly related to cancer treatment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mood alteration - Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="34" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="21" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" events="28" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="23" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The 4 Mantle Cell participants were not evaluated for Outcome Measures due to their low enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Javier Pinilla-Ibarz</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-1387</phone>
      <email>javier.pinilla@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

